(Q34658794)

3 August 2017

title

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer (English)

1 reference

3 August 2017

1 reference

5

Mathias Uhlén

1 reference

3 August 2017

6

Karin Jirström

1 reference

3 August 2017

7

Per-Uno Malmström

1 reference

3 August 2017

Karolina Boman

1

1 reference

3 August 2017

Ulrika Segersten

series ordinal

2

1 reference

3 August 2017

Göran Ahlgren

series ordinal

3

1 reference

3 August 2017

Jakob Eberhard

series ordinal

4

1 reference

3 August 2017

publication date

8 April 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

page(s)

17

1 reference

Creative Commons Attribution 2.0 Generic

3 August 2017

copyright license

start time

8 April 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Economic aspects of bladder cancer: what are the benefits and costs?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

T1G3 bladder cancer--indications for early cystectomy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

The treatment of advanced bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Biology and management of bladder cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635919

Urine cytology discrepancies: frequency, causes, and outcomes

7 July 2018

1 reference

12 December 2020

DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy

1 reference

12 December 2020

HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours

1 reference

12 December 2020

Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2490-13-17

1 reference

3 August 2017

1 reference

3 August 2017

1 reference